Recruiting
Phase 2

Isoquercetin

Sponsor:

Memorial Sloan Kettering Cancer Center

Code:

NCT07303894

Conditions

Ovarian Cancer

Epithelial Ovarian Cancer

Serous Ovarian Tumor

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Isoquercetin

Placebo

Study Details

Brief summary:

The purpose of this study is to test whether isoquercetin can reduce markers in the blood that may indicate the risk of blood clots in people with ovarian cancer. The effects of isoquercetin will be compared with those of a placebo.

Conditions

Ovarian Cancer

Epithelial Ovarian Cancer

Serous Ovarian Tumor

Study ID

NCT07303894

Start date

Jan 22, 2026

Status verified date

Jul, 2026

Completion date

Jan, 2032

Anticipated

Primary completion date

Jan, 2032

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Participants must have histological- or cytological-confirmed ovarian cancer (epithelial, serous, or clear cell) and be receiving first-line chemotherapy (day 1 of isoquercetin should align with day 1 of cycle 1 or 2 of chemotherapy) for neoadjuvant, adjuvant, or advanced settings.
  • Minimum age 18 years
  • Life expectancy of greater than 6 months.
  • ECOG performance status <2
  • Participants must have preserved organ and marrow function as defined below:

  • Platelet count > 50,000/mcL
  • Prothrombin time (PT) and partial thromboplastin time (PTT) < 1.5 x institutional upper limit of normal (ULN)
  • Total bilirubin < 3 x ULN without liver metastases and <5 x ULN in presence of liver metastases.
  • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3 X ULN without liver metastases and <5 x ULN in the presence of liver metastases.
  • Estimated creatinine clearance (CrCl >30 ml/min)
  • The effects of isoquercetin on the developing human fetus are unknown. For this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
  • Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

  • Prior history of documented venous thromboembolic event within the last 2 years (excluding central line associated events whereby patients completed anticoagulation)
  • Active bleeding or high risk for bleeding (e.g., known acute gastrointestinal ulcer)
  • History of significant hemorrhage (requiring hospitalization or transfusion) outside of a surgical setting within the last 24 months
  • Familial bleeding diathesis
  • Known diagnosis of disseminated intravascular coagulation (DIC)
  • Currently receiving anticoagulant therapy
  • Current daily use of aspirin, clopidogrel (Plavix), cilostazol (Pletal), aspirin-dipyridamole (Aggrenox) (within 10 days) or considered to use regular use of higher doses of non-steroidal anti-inflammatory agents as determined by the treating physician (e.g ibuprofen > 800 mg daily or equivalent)
  • Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
  • Known intolerance of (iso)quercetin, niacin or ascorbic acid (including known G6PD deficiency).
  • Participants with known brain metastases
  • Pregnant women are excluded from this study because isoquercetin is a PDI inhibitor with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk of adverse events in nursing infants secondary to treatment of the mother with isoquercetin, breastfeeding should be discontinued if the mother is treated with isoquercetin.

Study Design

Enrollment

90 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

placebo comparator: Cohort A: Placebo

experimental: Cohort B: Isoquercetin daily

experimental: Cohort C: Isoquercetin twice daily

Interventions

Isoquercetin

Cohort B and Cohort C will take isoquercetin

Placebo

Placebo

Primary outcome measure

  • Level of PDI-sensitive, platelet-dependent thrombin generation measured as compared to baseline [ Time Frame: up to 6 weeks from baseline ]

Central Contacts and Locations

Central contacts

Jeffrey Zwicker, MD

646-608-3723zwickerj@mskcc.org

Elizabeth Jewell, MD

212-639-3366jewelle@mskcc.org

Locations

Memorial Sloan Kettering Basking Ridge (All Protocol Activities)

Recruiting

Basking Ridge, New Jersey, United States, 07920

Contacts

Jeffrey A Zwicker, MD

646-608-3723

Memorial Sloan Kettering Monmouth (All Protocol Activities)

Recruiting

Middletown, New Jersey, United States, 07748

Contacts

Jeffrey Zwicker, MD

646-608-3723

Memorial Sloan Kettering Bergen (All Protocol Activities)

Recruiting

Montvale, New Jersey, United States, 07645

Contacts

Jeffrey Zwicker, MD

646-608-3723

Memorial Sloan Kettering Suffolk-Commack (All Protocol Activities )

Recruiting

Commack, New York, United States, 11725

Contacts

Jeffrey Zwicker, MD

646-608-3723

Memorial Sloan Kettering Westchester (All Protocol Activities)

Recruiting

Harrison, New York, United States, 10604

Contacts

Jeffrey Zwicker, MD

646-608-3723

Memorial Sloan Kettering Cancer Center (All Protocol Activites)

Recruiting

New York, New York, United States, 10065

Contacts

Jeffrey Zwicker, MD

646-608-3723

Memorial Sloan Kettering Nassau (All protocol activities)

Recruiting

Rockville Centre, New York, United States, 11553

Contacts

Jeffrey Zwicker, MD

646-608-3723

More Information

Sponsor

Memorial Sloan Kettering Cancer Center

Last update posted

Jul 29, 2026

Last verified

Jul, 2026

Keywords

  • Ovarian Cancer
  • Epithelial Ovarian Cancer
  • Serous Ovarian Tumor
  • Isoquercetin
  • Memorial Sloan Kettering Cancer Center
  • 25-060

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Memorial Sloan Kettering Cancer Center on 2026-07-29.